324 related articles for article (PubMed ID: 8970537)
21. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
23. 131I therapy of toxic and non-toxic goiters.
Beckers C
Q J Nucl Med; 1999 Dec; 43(4):291-6. PubMed ID: 10731779
[TBL] [Abstract][Full Text] [Related]
24. [Development of Basedow disease after radioiodine therapy for nodular goiter].
Cseke B; Balázs C
Orv Hetil; 2003 Nov; 144(47):2327-9. PubMed ID: 14725052
[TBL] [Abstract][Full Text] [Related]
25. Radioiodine therapy for thyroid volume reduction of large goitres.
Bachmann J; Kobe C; Bor S; Rahlff I; Dietlein M; Schicha H; Schmidt M
Nucl Med Commun; 2009 Jun; 30(6):466-71. PubMed ID: 19381116
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy (I 131).
Khanna CM; Magdum M; Ravishankar L; Dham DN; Chugh P
J Assoc Physicians India; 1996 Feb; 44(2):102-5. PubMed ID: 10999060
[TBL] [Abstract][Full Text] [Related]
27. [Results of the definitive treatment of autonomy in iodine deficiency goiter].
Emrich D; Reinhardt M
Nuklearmedizin; 1989 Feb; 28(1):11-6. PubMed ID: 2710642
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of two schedules of treatment for toxic multinodular goitre with radioiodine therapy.
Khanna CM; Magdam M; Ravishankar L; Dham DN; Chugh P
J Assoc Physicians India; 1995 Oct; 43(10):685-8. PubMed ID: 8773004
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
30. Radioiodine treatment of hyperthyroidism in a pregnant women.
Berg GE; Nyström EH; Jacobsson L; Lindberg S; Lindstedt RG; Mattsson S; Niklasson CA; Norén AH; Westphal OG
J Nucl Med; 1998 Feb; 39(2):357-61. PubMed ID: 9476950
[TBL] [Abstract][Full Text] [Related]
31. [Long-term effect of 131I therapy of multinodular non-toxic goiter].
Nygaard B; Hegedüs L; Gervil M; Jensen HH; Søe-Jensen P; Hansen JE
Ugeskr Laeger; 1994 Sep; 156(39):5699-703. PubMed ID: 7985257
[TBL] [Abstract][Full Text] [Related]
32. Risk of thyroid cancer after exposure to 131I in childhood.
Cardis E; Kesminiene A; Ivanov V; Malakhova I; Shibata Y; Khrouch V; Drozdovitch V; Maceika E; Zvonova I; Vlassov O; Bouville A; Goulko G; Hoshi M; Abrosimov A; Anoshko J; Astakhova L; Chekin S; Demidchik E; Galanti R; Ito M; Korobova E; Lushnikov E; Maksioutov M; Masyakin V; Nerovnia A; Parshin V; Parshkov E; Piliptsevich N; Pinchera A; Polyakov S; Shabeka N; Suonio E; Tenet V; Tsyb A; Yamashita S; Williams D
J Natl Cancer Inst; 2005 May; 97(10):724-32. PubMed ID: 15900042
[TBL] [Abstract][Full Text] [Related]
33. Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro.
Lundh C; Nordén MM; Nilsson M; Forssell-Aronsson E
J Nucl Med; 2007 Mar; 48(3):481-6. PubMed ID: 17332627
[TBL] [Abstract][Full Text] [Related]
34. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
[TBL] [Abstract][Full Text] [Related]
35. 131I effective half-life and dosimetry in thyroid cancer patients.
Remy H; Borget I; Leboulleux S; Guilabert N; Lavielle F; Garsi J; Bournaud C; Gupta S; Schlumberger M; Ricard M
J Nucl Med; 2008 Sep; 49(9):1445-50. PubMed ID: 18703593
[TBL] [Abstract][Full Text] [Related]
36. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Légal JD; Schlumberger M; Aubert B; Beron-Gaillard N; Gaussen A; Parmentier C
J Nucl Med; 1997 Mar; 38(3):377-80. PubMed ID: 9074522
[TBL] [Abstract][Full Text] [Related]
37. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA
J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
[TBL] [Abstract][Full Text] [Related]
38. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
39. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
